Fig. 2From: The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cellsPalbociclib modulates the activation/expression of cell cycle-related proteins in a dose- and time-dependent manner. MDA-MB-231 and HCC38 cells were treated with increasing concentrations of palbociclib for 24Â h (a) or with a fixed drug concentration for different periods of time (b). The expression of the indicated proteins was analyzed by Western blotting. Results are representative of three independent experimentsBack to article page